<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01670812</url>
  </required_header>
  <id_info>
    <org_study_id>JSPH-CLL-001</org_study_id>
    <nct_id>NCT01670812</nct_id>
  </id_info>
  <brief_title>Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia</brief_title>
  <official_title>Clinical Study of Chemoimmunotherapy With Fresh Frozen Plasma, High Dose Methylprednisolone and Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate efficacy and safety of fresh frozen plasma(FFP),&#xD;
      high dose methylprednisolone(HDMP) and rituximab for ultra-high risk chronic lymphocytic&#xD;
      leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic lymphocytic leukemia remains incurable and particularly in ultra-high risk subgroup,&#xD;
      and the prognosis of these patients is still dismal.&#xD;
&#xD;
      This is a phase III, multicenter perspective clinical trial of combination of fresh frozen&#xD;
      plasma(FFP), high dose methylprednisolone(HDMP) and rituximab for ultra-high risk chronic&#xD;
      lymphocytic leukemiaThe. The main purpose of this study is to investigate efficacy and safety&#xD;
      of this combinated regimen in subgroup of CLL patients.&#xD;
&#xD;
      All the enrolled patients will be followed during and after the treatment period up to one&#xD;
      year. Interim and final evaluation will be done after each cycle of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>one year</time_frame>
    <description>overall response rate after treated by FFP+HDMP+Rituximab regimen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>one year</time_frame>
    <description>progression free survival after treatment of FFP+HDMP+Rituximab for ultra-high risk CLL patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>one year</time_frame>
    <description>overall survival after treatment of FFP+HDMP+Rituximab for ultra-high risk CLL patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>up to 30 days after last dose of treatment</time_frame>
    <description>Number of Participants with Adverse Events, and evaluated standard is according to common terminology criteria adverse events(CTCAE) version 4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>FFP+HDMP+Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fresh frozen plasma 400ml IV day0, Rituximab: 375 mg/m2 IV day0(after infusion of FFP), methylprednisolone 1g/m2(up to 1.5g) IV day1-day5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FFP+HDMP+Rituximab</intervention_name>
    <description>This is a single arm, multicenter clinical trial, and the regimen including Fresh frozen plasma 400ml IV day0, Rituximab: 375 mg/m2 IV day0(after infusion of FFP), methylprednisolone 1g/m2(up to 1.5g) IV day1-day5</description>
    <arm_group_label>FFP+HDMP+Rituximab</arm_group_label>
    <other_name>fresh frozen plasma</other_name>
    <other_name>methylprednisolone</other_name>
    <other_name>rituximab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18-80 years old.&#xD;
&#xD;
          2. Diagnosis of chronic lymphocytic leukemia.&#xD;
&#xD;
          3. Active disease meeting at least one of the International Workshop on Chronic&#xD;
             Lymphocytic Leukemia 2008 criteria for requiring treatment.&#xD;
&#xD;
          4. Ultra-high risk CLL(Meets at least one of the following criteria) (1)ultra high-risk&#xD;
             genetics (17p deletion and/or TP53 mutation) (2)short PFS(&lt;24 months)after intense&#xD;
             immunochemotherapy treatment(i.e. FCR, FR, PCR, BR etc) (3)fludarabine-refractory&#xD;
&#xD;
          5. Understand and voluntarily sign an informed consent form, able to adhere to the study&#xD;
             visit schedule and other protocol requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe allergic constitution or asthma.&#xD;
&#xD;
          2. Recent myocardial infarction or hypotension.&#xD;
&#xD;
          3. ECOG performance status of ≤ 2 at study entry.&#xD;
&#xD;
          4. Active hepatitis B(DNA &gt;1×103/ml)&#xD;
&#xD;
          5. Severe and uncontrolled diabetes mellitus.&#xD;
&#xD;
          6. Severe and uncontrolled hypertension(BP&gt; 150/90 mmHg after treatment).&#xD;
&#xD;
          7. Active and uncontrolled systematic infection which need treatment of antibiotics.&#xD;
&#xD;
          8. Clinical symptoms of dysfunction of central nervous system.&#xD;
&#xD;
          9. Unstable and severe gastrorrhagia and peptic ulcer.&#xD;
&#xD;
         10. Major surgery within three weeks.&#xD;
&#xD;
         11. Any potential drug abuse, medical, psychological or social conditions which may&#xD;
             disturb this investigation and assessment.&#xD;
&#xD;
         12. In any conditions which investigator considered ineligible for this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Xu, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LEI FAN, M.D., Ph.D.</last_name>
    <phone>+86 25 6813 6034</phone>
    <email>fanlei_fl@yahoo.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First affiliated Hospital of AnHui Medical Universtiy</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zimin Sun, M.D., Ph.D.</last_name>
      <email>Zmsun_vip@163.com</email>
    </contact>
    <investigator>
      <last_name>Zimin Sun, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TongJi Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianfeng Zhou, M.D., Ph.D.</last_name>
      <email>zhougene@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Jianfeng Zhou, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ChangZhou First People's Hospital</name>
      <address>
        <city>ChangZhou</city>
        <state>Jiangsu</state>
        <zip>213003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>XiangShan Cao, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>XiangShan Cao, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ChangZhou No.2 People's Hospital</name>
      <address>
        <city>ChangZhou</city>
        <state>Jiangsu</state>
        <zip>213011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Zhou, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Min Zhou, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HuaiAn First People's Hospital</name>
      <address>
        <city>HuaiAn</city>
        <state>Jiangsu</state>
        <zip>223300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Yu, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Liang Yu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NanJing First People's Hospital</name>
      <address>
        <city>NanJing</city>
        <state>Jiangsu</state>
        <zip>210006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YanLi Xu, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>YanLi Xu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>JiangSu Province Hospital</name>
      <address>
        <city>NanJing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LEI FAN, Dr.</last_name>
      <phone>86 25 6813 6034</phone>
    </contact>
    <investigator>
      <last_name>WEI XU, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>JiangSu Province Hospital of TCM</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuemei Sun, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Xuemei Sun, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WuXi People's Hospital</name>
      <address>
        <city>WuXi</city>
        <state>Jiangsu</state>
        <zip>214023</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun Zhuang, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>YunFeng Shen, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ZhenJiang First People's Hospital</name>
      <address>
        <city>ZhenJiang</city>
        <state>Jiangsu</state>
        <zip>212002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Zhu, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Yan Zhu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Wang, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Xin Wang, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TongJi Medical University affiliated TongJi Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aibin Liang, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Aibin Liang, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China School of Medicine, West China Hospital, Sichuan University</name>
      <address>
        <city>Chendu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ting Liu, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Ting Liu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology &amp; Blood Diseases Hospital</name>
      <address>
        <city>TianJin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lugui Qiu, M.D., Ph.D.</last_name>
      <phone>+86 22 2390 9999</phone>
      <email>drqiu99@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Lugui Qiu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Xu W, Miao KR, Zhu DX, Fang C, Zhu HY, Dong HJ, Wang DM, Wu YJ, Qiao C, Li JY. Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia. Int J Cancer. 2011 May 1;128(9):2192-201. doi: 10.1002/ijc.25560.</citation>
    <PMID>20635386</PMID>
  </reference>
  <reference>
    <citation>Xu W, Miao KR, Hong M, Zhu DX, Fang C, Dong HJ, Wang DM, Cao X, Li JY. High-dose methylprednisolone can induce remissions in patients with fludarabine-refractory chronic lymphocytic leukaemia. Eur J Cancer. 2010 Aug;46(12):2145-9. doi: 10.1016/j.ejca.2010.04.021. Epub 2010 Jun 4.</citation>
    <PMID>20627536</PMID>
  </reference>
  <reference>
    <citation>Dungarwalla M, Evans SO, Riley U, Catovsky D, Dearden CE, Matutes E. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica. 2008 Mar;93(3):475-6. doi: 10.3324/haematol.11903.</citation>
    <PMID>18310545</PMID>
  </reference>
  <reference>
    <citation>Klepfish A, Gilles L, Ioannis K, Rachmilewitz EA, Schattner A. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions &amp; clinical results in refractory CLL. Ann N Y Acad Sci. 2009 Sep;1173:865-73. doi: 10.1111/j.1749-6632.2009.04803.x. Erratum In: Ann N Y Acad Sci. 2010 Aug;1204:198. Eliezer, Rachmilewitz [corrected to Rachmilewitz, Eliezer A]; Ami, Schattner [corrected to Schattner, Ami].</citation>
    <PMID>19758239</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>August 19, 2012</study_first_submitted>
  <study_first_submitted_qc>August 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2012</study_first_posted>
  <last_update_submitted>August 19, 2012</last_update_submitted>
  <last_update_submitted_qc>August 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>WEI XU</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>chronic lymphocytic leukemia</keyword>
  <keyword>ultra-high risk</keyword>
  <keyword>fresh frozen plasma</keyword>
  <keyword>methylprednisolone</keyword>
  <keyword>rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT01670812
org study id: JSPH-CLL-001
nct id: NCT01670812
lead sponsor: 
has dmc: Yes
The purpose of this study is to investigate efficacy and safety of fresh frozen plasma(FFP),
      high dose methylprednisolone(HDMP) and rituximab for ultra-high risk chronic lymphocytic
      leukemia.
Chronic lymphocytic leukemia remains incurable and particularly in ultra-high risk subgroup,
      and the prognosis of these patients is still dismal.

      This is a phase III, multicenter perspective clinical trial of combination of fresh frozen
      plasma(FFP), high dose methylprednisolone(HDMP) and rituximab for ultra-high risk chronic
      lymphocytic leukemiaThe. The main purpose of this study is to investigate efficacy and safety
      of this combinated regimen in subgroup of CLL patients.

      All the enrolled patients will be followed during and after the treatment period up to one
      year. Interim and final evaluation will be done after each cycle of treatment.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: overall response rate
time frame: one year
description: overall response rate after treated by FFP+HDMP+Rituximab regimen
measure: progression free survival
time frame: one year
description: progression free survival after treatment of FFP+HDMP+Rituximab for ultra-high risk CLL patients.
measure: overall survival
time frame: one year
description: overall survival after treatment of FFP+HDMP+Rituximab for ultra-high risk CLL patients
measure: Number of Participants with Adverse Events
time frame: up to 30 days after last dose of treatment
description: Number of Participants with Adverse Events, and evaluated standard is according to common terminology criteria adverse events(CTCAE) version 4.0
arm group label: FFP+HDMP+Rituximab
arm group type: Experimental
description: Fresh frozen plasma 400ml IV day0, Rituximab: 375 mg/m2 IV day0(after infusion of FFP), methylprednisolone 1g/m2(up to 1.5g) IV day1-day5.
intervention type: Drug
intervention name: FFP+HDMP+Rituximab
description: This is a single arm, multicenter clinical trial, and the regimen including Fresh frozen plasma 400ml IV day0, Rituximab: 375 mg/m2 IV day0(after infusion of FFP), methylprednisolone 1g/m2(up to 1.5g) IV day1-day5
arm group label: FFP+HDMP+Rituximab
other name: fresh frozen plasma
other name: methylprednisolone
other name: rituximab
criteria: 
gender: All
minimum age: 18 Years
maximum age: 80 Years
healthy volunteers: No
last name: Wei Xu, M.D., Ph.D.
role: Principal Investigator
affiliation: The First Affiliated Hospital with Nanjing Medical University
last name: LEI FAN, M.D., Ph.D.
phone: +86 25 6813 6034
email: fanlei_fl@yahoo.com.cn
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
country: China
citation: Xu W, Miao KR, Zhu DX, Fang C, Zhu HY, Dong HJ, Wang DM, Wu YJ, Qiao C, Li JY. Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia. Int J Cancer. 2011 May 1;128(9):2192-201. doi: 10.1002/ijc.25560.
PMID: 20635386
citation: Xu W, Miao KR, Hong M, Zhu DX, Fang C, Dong HJ, Wang DM, Cao X, Li JY. High-dose methylprednisolone can induce remissions in patients with fludarabine-refractory chronic lymphocytic leukaemia. Eur J Cancer. 2010 Aug;46(12):2145-9. doi: 10.1016/j.ejca.2010.04.021. Epub 2010 Jun 4.
PMID: 20627536
citation: Dungarwalla M, Evans SO, Riley U, Catovsky D, Dearden CE, Matutes E. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica. 2008 Mar;93(3):475-6. doi: 10.3324/haematol.11903.
PMID: 18310545
citation: Klepfish A, Gilles L, Ioannis K, Rachmilewitz EA, Schattner A. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL. Ann N Y Acad Sci. 2009 Sep;1173:865-73. doi: 10.1111/j.1749-6632.2009.04803.x. Erratum In: Ann N Y Acad Sci. 2010 Aug;1204:198. Eliezer, Rachmilewitz [corrected to Rachmilewitz, Eliezer A]; Ami, Schattner [corrected to Schattner, Ami].
PMID: 19758239
responsible party type: Principal Investigator
investigator affiliation: The First Affiliated Hospital with Nanjing Medical University
investigator full name: WEI XU
investigator title: Professor
mesh term: Leukemia
mesh term: Leukemia, Lymphoid
mesh term: Leukemia, Lymphocytic, Chronic, B-Cell
mesh term: Methylprednisolone
mesh term: Rituximab